Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

20183,378 citationsJournal Articlebronze Open Access

Authors

Gregory G. Schwartz · Inserm

Philippe Gabríel Steg · Inserm

Michael Szarek · State University of New York

Deepak L. Bhatt · Brigham and Women's Hospital

Vera Bittner · Inserm

Rafael Díaz · Inserm

Jay M. Edelberg · Inserm

Abstract

Among patients who had a previous acute coronary syndrome and who were receiving high-intensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than among those who received placebo. (Funded by Sanofi and Regeneron Pharmaceuticals; ODYSSEY OUTCOMES ClinicalTrials.gov number, NCT01663402 .).

Topics & Keywords

Lipoproteins and Cardiovascular Health Acute Myocardial Infarction Research Antiplatelet Therapy and Cardiovascular Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 379, Issue 22, pp. 2097-2107

DOI: 10.1056/nejmoa1801174

Field-Weighted Citation Impact: 333.81